Paliperidone Palmitate (Molecule of the Month for May 2017)
Invega
Paliperidone palmitate is a long-acting injectable formulation of paliperidone palmitoyl ester indicated for once-every 28 days injection after an initial titration period. Paliperidone is a dopamine antagonist and 5-HT2A antagonist of the atypical antipsychotic class of medications. Paliperidone is used to treat mania and at lower doses as maintenance for bipolar disorder. It is also indicated in the US by the FDA for schizophrenia and schizoaffective disorder. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing.
It is used for the treatment of schizophrenia and schizoaffective disorder. In a 2013 study in a comparison of 15 antipsychotic drugs in effectiveness in treating schizophrenic symptoms, paliperidone was ranked fifth, demonstrating standard-high effectiveness.
Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not identical, pathways.
Formal Chemical Name (IUPAC)
3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl palmitate
References
click on the picture of Paliperidone Palmitate above to interact
with the 3D model of the
Paliperidone Palmitate structure
(this will open a new browser window)
C39H57FN4O4
Update by Karl Harrison
(Molecule of the Month for
May 2017
)
All the images on this web site are are made available with a Creative Commons Attribution license and so can be used as long as the attribution © Karl Harrison 3DChem.com is written with the image. High resolution images and illustrations are available on request.